SubQ vs IM Semaglutide
Semaglutide is FDA-labeled for subcutaneous administration in branded and compounded formulations. Intramuscular administration is off-label and not the standard route in provider-reviewed metabolic optimization.
Subcutaneous semaglutide is the only provider-reviewed delivery route in the oMeds metabolic pathway.
Intramuscular semaglutide is off-label and outside oMeds clinical practice.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Can semaglutide be injected IM?
It is off-label; the standard, evidence-aligned route is subcutaneous.
Does injection site matter?
Subcutaneous abdomen, thigh, or upper arm are all acceptable per labeling.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment